Published in Lancet on November 19, 1988
Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol (2011) 25.66
Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosis. Neurohospitalist (2013) 0.78
Disease activity return during natalizumab treatment interruption in patients with multiple sclerosis. Neurology (2011) 4.25
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol (2009) 3.37
Differential diagnosis of suspected multiple sclerosis: a consensus approach. Mult Scler (2008) 3.28
TAP binds to the constitutive transport element (CTE) through a novel RNA-binding motif that is sufficient to promote CTE-dependent RNA export from the nucleus. EMBO J (1999) 2.83
Continuity and discontinuity of affective disorders and schizophrenia. Results of a controlled family study. Arch Gen Psychiatry (1993) 2.71
MS quality of life, depression, and fatigue improve after mindfulness training: a randomized trial. Neurology (2010) 2.33
Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy. Neurology (2011) 2.26
The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology (2007) 2.17
FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis. Neurology (2008) 2.07
Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry (1991) 2.05
Th17 central memory T cells are reduced by FTY720 in patients with multiple sclerosis. Neurology (2010) 2.04
Obstetric complications and age at onset in schizophrenia: an international collaborative meta-analysis of individual patient data. Am J Psychiatry (1997) 1.94
Myelin autoreactivity in multiple sclerosis: recognition of myelin basic protein in the context of HLA-DR2 products by T lymphocytes of multiple-sclerosis patients and healthy donors. Proc Natl Acad Sci U S A (1990) 1.93
Self glycolipids as T-cell autoantigens. Eur J Immunol (1999) 1.93
Clinical and radiological predictors of recanalisation and outcome of 40 patients with acute basilar artery occlusion treated with intra-arterial thrombolysis. J Neurol Neurosurg Psychiatry (2004) 1.90
MRI criteria for MS in patients with clinically isolated syndromes. Neurology (2010) 1.90
A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS. Neurology (2002) 1.86
Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology (2011) 1.83
Oral fingolimod (FTY720) in multiple sclerosis: two-year results of a phase II extension study. Neurology (2009) 1.78
Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology (2011) 1.75
Completed suicide, ideation and attempt in attention deficit hyperactivity disorder. Acta Psychiatr Scand (2011) 1.73
Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J Clin Invest (1993) 1.73
The alphabeta T cell response to self-glycolipids shows a novel mechanism of CD1b loading and a requirement for complex oligosaccharides. Immunity (2000) 1.72
Carotid dissection with and without ischemic events: local symptoms and cerebral artery findings. Neurology (2001) 1.71
The Fatigue Scale for Motor and Cognitive Functions (FSMC): validation of a new instrument to assess multiple sclerosis-related fatigue. Mult Scler (2009) 1.65
Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results. Mult Scler (2009) 1.65
Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multi-centre fMRI study. Eur J Neurol (2008) 1.63
Validity of the five-item WHO Well-Being Index (WHO-5) in an elderly population. Eur Arch Psychiatry Clin Neurosci (2001) 1.62
Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals. Neurology (1990) 1.61
A genetic variation of cathepsin D is a major risk factor for Alzheimer's disease. Ann Neurol (2000) 1.61
Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis. Brain Res Brain Res Rev (2001) 1.59
CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects. Neurology (2002) 1.58
Computer assisted retraining of attentional impairments in patients with multiple sclerosis. J Neurol Neurosurg Psychiatry (1998) 1.57
MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology (2007) 1.56
Schizoaffective disorder and affective disorders with mood-incongruent psychotic features: keep separate or combine? Evidence from a family study. Am J Psychiatry (1992) 1.56
Reduced glucose metabolism in the frontal cortex and basal ganglia of multiple sclerosis patients with fatigue: a 18F-fluorodeoxyglucose positron emission tomography study. Neurology (1997) 1.55
Neutralizing antibodies during treatment of secondary progressive MS with interferon beta-1b. Neurology (2003) 1.54
Ethics of placebo-controlled clinical trials in multiple sclerosis: a reassessment. Neurology (2008) 1.53
Plasma 24S-hydroxycholesterol (cerebrosterol) is increased in Alzheimer and vascular demented patients. J Lipid Res (2000) 1.51
The challenge of follow-on biologics for treatment of multiple sclerosis. Neurology (2009) 1.49
Acute and chronic neuroborreliosis with and without CNS involvement: a clinical, MRI, and HLA study of 27 cases. J Neurol (1991) 1.49
Natalizumab reduces visual loss in patients with relapsing multiple sclerosis. Neurology (2007) 1.45
Risk factors for new depressive episodes in primary health care: an international prospective 12-month follow-up study. Psychol Med (2002) 1.44
Polymorphisms in glutathione S-transferase omega-1 and AD, vascular dementia, and stroke. Neurology (2004) 1.36
MRI T2 lesion burden in multiple sclerosis: a plateauing relationship with clinical disability. Neurology (2006) 1.29
Can the Expanded Disability Status Scale be assessed by telephone? Mult Scler (2003) 1.28
Increased levels of inflammatory chemokines in amyotrophic lateral sclerosis. Eur J Neurol (2009) 1.27
Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology (2011) 1.25
MSBase: an international, online registry and platform for collaborative outcomes research in multiple sclerosis. Mult Scler (2006) 1.25
Correlations between changes in disability and T2-weighted brain MRI activity in multiple sclerosis: a follow-up study. Neurology (1995) 1.19
Generalized anxiety disorder (ICD-10) in primary care from a cross-cultural perspective: a valid diagnostic entity? Acta Psychiatr Scand (2000) 1.18
Black holes in multiple sclerosis: definition, evolution, and clinical correlations. Acta Neurol Scand (2009) 1.17
24S-hydroxycholesterol in cerebrospinal fluid is elevated in early stages of dementia. J Psychiatr Res (2001) 1.16
Moyamoya disease and Moyamoya syndrome: experience in Europe; choice of revascularisation procedures. Acta Neurochir (Wien) (2003) 1.15
Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis. Brain (1998) 1.15
Polymorphism in the cholesterol 24S-hydroxylase gene is associated with Alzheimer's disease. Mol Psychiatry (2002) 1.14
Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol (2002) 1.10
A genetic variation of the inflammatory cytokine interleukin-6 delays the initial onset and reduces the risk for sporadic Alzheimer's disease. Ann Neurol (1999) 1.10
The surgeon's view of the anterior ethmoid artery. Clin Otolaryngol (2006) 1.10
Proton MR spectroscopy detects a relative decrease of N-acetylaspartate in the medial temporal lobe of patients with AD. Neurology (2000) 1.10
Multicenter assessment of reliability of cranial MRI. Neurobiol Aging (2005) 1.08
A knowledge-driven interaction analysis reveals potential neurodegenerative mechanism of multiple sclerosis susceptibility. Genes Immun (2011) 1.08
Predictors of relapse rate in MS clinical trials. Neurology (2005) 1.06
Genetic association of a cystatin C gene polymorphism with late-onset Alzheimer disease. Arch Neurol (2000) 1.06
Schizophrenia and complications of pregnancy and labor: an individual patient data meta-analysis. Schizophr Bull (1999) 1.06
MR imaging in multiple sclerosis: review and recommendations for current practice. AJNR Am J Neuroradiol (2009) 1.05
Temporal profile of lymphocyte counts and relationship with infections with fingolimod therapy. Mult Scler (2013) 1.05
Fatigue in multiple sclerosis: relation to depression, physical impairment, personality and action control. Mult Scler (2007) 1.05
A multicenter (1)H-MRS study of the medial temporal lobe in AD and MCI. Neurology (2009) 1.05
Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial. Neurology (2012) 1.05
Short echo time proton MR spectroscopic imaging. J Comput Assist Tomogr (1993) 1.05
Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition. Exp Brain Res (2008) 1.04
The concreteness effect: evidence for dual coding and context availability. Brain Lang (2000) 1.04
Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport (2000) 1.04
Anterior pituitary axis hormones and outcome in acute ischaemic stroke. J Intern Med (2011) 1.03
Decrease of N-acetylaspartate in the MTL correlates with cognitive decline of AD patients. Neurology (2001) 1.02
Distal posterior inferior cerebellar artery aneurysms: clinical characteristics and surgical management. Acta Neurochir (Wien) (2005) 1.02
Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study. AJNR Am J Neuroradiol (2000) 1.02
Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis. Neurology (2006) 1.01
Clinical-MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. Neurology (2001) 1.01
Rate of brain atrophy in relapsing MS decreases during treatment with IFNbeta-1a. Neurology (2005) 1.01
Structural and neurobehavioral delay in postnatal brain development of preterm infants. Pediatr Res (1996) 1.00
Altered levels of plasma 24S- and 27-hydroxycholesterol in demented patients. Neurosci Lett (2004) 1.00
Oral fingolimod (FTY720) in relapsing multiple sclerosis: impact on health-related quality of life in a phase II study. Mult Scler (2011) 0.99
[Facial myokymia caused by pontine lesions and central fever in multiple sclerosis--case report]. Schweiz Rundsch Med Prax (1991) 0.98
Reproducibility of fMRI in the clinical setting: implications for trial designs. Neuroimage (2008) 0.98
Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis. Neuroradiology (2010) 0.97
Dynamic susceptibility contrast MR imaging of plaque development in multiple sclerosis: application of an extended blood-brain barrier leakage correction. J Magn Reson Imaging (2000) 0.97
The expression profile of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in lesions and normal appearing white matter of multiple sclerosis. Brain (2001) 0.97
Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. Mult Scler (2013) 0.97
[Computerized tomography of paranasal sinuses--a preoperative check list]. Laryngorhinootologie (1997) 0.97
Solitary fibrous tumor of the orbit--two cases and a review of the literature. Eur Arch Otorhinolaryngol (2004) 0.97
Association between a functional polymorphism in the monoamine oxidase A gene promoter and major depressive disorder. Am J Med Genet (2000) 0.96
Sensory gating deficit expressed by a disturbed suppression of the P50 event-related potential in patients with Alzheimer's disease. Am J Psychiatry (2001) 0.95
Amplitude reduction of the mismatch negativity in first-degree relatives of patients with schizophrenia. Neurosci Lett (2001) 0.95
Screening for depression in the elderly: a study on misclassification by screening instruments and improvement of scale performance. Prog Neuropsychopharmacol Biol Psychiatry (1999) 0.94
Stress hormones predict cerebrovascular re-events after transient ischemic attacks. Neurology (2011) 0.94
Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks. Mult Scler (2010) 0.94